Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting

Nat Rev Clin Oncol. 2018 Feb;15(2):77-78. doi: 10.1038/nrclinonc.2017.185. Epub 2017 Nov 28.

Abstract

2017 has been full of new discoveries that will influence the treatment of colorectal cancer. In the adjuvant setting, 3 months of chemotherapy might now be considered a new standard of care. Various other new treatments and promising biomarkers have also become available that will improve survival outcomes and the quality of life of many patients with metastatic disease.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Chemotherapy, Adjuvant / adverse effects
  • Chemotherapy, Adjuvant / trends*
  • Clinical Trials as Topic
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / epidemiology
  • Colorectal Neoplasms / immunology
  • Humans
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Nivolumab / therapeutic use
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / therapeutic use*
  • Progression-Free Survival

Substances

  • Antibodies, Monoclonal, Humanized
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab